Philips Acquires SpectraWAVE: Revolutionizing Coronary Artery Imaging with AI Technology
Royal Philips, a global leader in health technology, has announced its acquisition of SpectraWAVE, Inc., an innovator in Enhanced Vascular Imaging (EVI) technology for coronary arteries and AI-based medical imaging. SpectraWAVE's technologies offer advanced solutions for treating patients with coronary artery disease, a prevalent heart condition affecting millions worldwide. The acquisition aims to enhance Philips' image-guided therapy portfolio and improve patient care outcomes through innovative technologies.
The partnership with SpectraWAVE allows Philips to integrate AI-powered intravascular imaging and physiological assessment technologies into its image-guided therapy ecosystem. This integration will enable clinicians to make more informed decisions, guide treatments effectively, and confirm treatment outcomes in a single setting. By expanding its portfolio with breakthrough AI technologies, Philips aims to provide high-quality care to patients with coronary disease and support clinicians in delivering better outcomes.
SpectraWAVE's HyperVue Imaging System combines DeepOCT and NIRS technologies to provide detailed structural and compositional images of coronary arteries during percutaneous coronary interventions. This novel imaging platform, along with Philips' existing technologies, offers clinicians a comprehensive intravascular imaging toolbox to tailor guidance for each patient and lesion. Additionally, SpectraWAVE's X1-FFR solution calculates Fractional Flow Reserve from a single coronary angiogram, providing non-invasive ischemia assessment and enhancing percutaneous coronary intervention workflows.
Philips' image-guided therapy portfolio, anchored by the Azurion platform, brings together advanced interventional tools in a single environment to support a wide range of procedures across various medical specialties. With the addition of SpectraWAVE's technologies, Philips aims to expand clinician choice and integrate AI across its coronary portfolio to improve procedural efficiency and patient outcomes. The acquisition marks a significant step in advancing minimally invasive image-guided therapy procedures and enhancing the role of AI in healthcare technology.
Overall, the acquisition of SpectraWAVE by Royal Philips underscores the company's commitment to driving innovation in image-guided therapy and improving patient care through advanced technologies. By integrating AI-powered solutions into its portfolio, Philips aims to empower clinicians with the tools they need to deliver high-quality care to patients with coronary artery disease and other cardiovascular conditions.